Literature DB >> 15034243

The role of itraconazole in preventing and treating systemic fungal infections in immunocompromised patients.

M Potter1, J P Donnelly.   

Abstract

The increasing use of immunosuppressive chemotherapy and allogeneic transplants for haematological malignancies has increased the number of patients at risk of systemic fungal infections (SFIs). A number of antifungal agents are now available. This paper reports the deliberations of an expert panel that considered the role of itraconazole. It concluded that itraconazole has an important role in the prophylaxis and treatment of SFIs whether proven or not. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15034243     DOI： 10.1159/000076530

Source DB:  PubMed          Journal:  Acta Haematol        ISSN： 0001-5792            Impact factor:   2.195


  7 in total

1.  Drug interaction between oral solution itraconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplantation recipients: an association with bioavailability of oral solution itraconazole.

Authors:  Takehiko Mori; Yoshinobu Aisa; Jun Kato; Yukinori Nakamura; Yasuo Ikeda; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2009-05-27       Impact factor: 2.490

2.  Economic evaluation of intravenous itraconazole for presumed systemic fungal infections in neutropenic patients in Korea.

Authors:  K Moeremans; L Annemans; Ji-So Ryu; Kang-Won Choe; Wan-Shik Shine
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

3.  Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states.

Authors:  Ahmad Y Abuhelwa; David J R Foster; Stuart Mudge; David Hayes; Richard N Upton
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

4.  Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects.

Authors:  Julian Lindsay; Stuart Mudge; George R Thompson
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

5.  Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia.

Authors:  M Döring; M Eikemeier; K M Cabanillas Stanchi; U Hartmann; M Ebinger; C-P Schwarze; A Schulz; R Handgretinger; I Müller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-02-14       Impact factor: 3.267

6.  Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation.

Authors:  M Döring; O Blume; S Haufe; U Hartmann; A Kimmig; C-P Schwarze; P Lang; R Handgretinger; I Müller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-10-31       Impact factor: 3.267

7.  Open-Label Crossover Oral Bioequivalence Pharmacokinetics Comparison for a 3-Day Loading Dose Regimen and 15-Day Steady-State Administration of SUBA-Itraconazole and Conventional Itraconazole Capsules in Healthy Adults.

Authors:  George R Thompson; Phoebe Lewis; Stuart Mudge; Thomas F Patterson; Bruce P Burnett
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.